Discovering argenx And 2 More Stocks That May Be Priced Below Estimated Value
In This Article:
As global markets react to China's robust stimulus measures, with U.S. stocks reaching record highs and European indices rebounding, investors are keenly observing the shifting economic landscape. In this context of heightened market activity and optimism around technological advancements, identifying undervalued stocks becomes crucial for those looking to capitalize on potential growth opportunities.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| First Internet Bancorp (NasdaqGS:INBK) | US$31.37 | US$62.52 | 49.8% |
| Gaming Realms (AIM:GMR) | ￡0.382 | ￡0.76 | 49.8% |
| Zhejiang Great Shengda PackagingLtd (SHSE:603687) | CN￥7.11 | CN￥14.16 | 49.8% |
| HSS Engineers Berhad (KLSE:HSSEB) | MYR1.07 | MYR2.14 | 50% |
| TSE (KOSDAQ:A131290) | ?50200.00 | ?100124.32 | 49.9% |
| Sejin Heavy Industries (KOSE:A075580) | ?7480.00 | ?14914.79 | 49.8% |
| Ta-Yuan Cogeneration (TPEX:8931) | NT$49.20 | NT$97.85 | 49.7% |
| ABCO Electronics (KOSDAQ:A036010) | ?5760.00 | ?11488.39 | 49.9% |
| Akeso (SEHK:9926) | HK$67.30 | HK$133.87 | 49.7% |
| Digital China Holdings (SEHK:861) | HK$2.96 | HK$5.88 | 49.7% |
We'll examine a selection from our screener results.
argenx
Overview: argenx SE is a biotechnology company focused on developing therapies for autoimmune diseases across the United States, Japan, Europe, the Middle East, Africa, and China, with a market cap of €29.70 billion.
Operations: The company generates its revenue primarily from its biotechnology segment, which amounted to $1.66 billion.
Estimated Discount To Fair Value: 41.9%
argenx is trading significantly below its estimated fair value, with a discounted cash flow analysis suggesting it is highly undervalued. Recent earnings show strong revenue growth, reaching US$489.43 million in Q2 2024, up from US$281.04 million a year ago, and a shift to profitability with a net income of US$29.07 million. The approval of VYVGART Hytrulo for CIDP enhances its product portfolio and potential cash flows despite past shareholder dilution and insider selling concerns.
Hangzhou Tigermed Consulting
Overview: Hangzhou Tigermed Consulting Co., Ltd offers contract research organization services both within China and internationally, with a market capitalization of CN￥56.69 billion.
Operations: Revenue Segments (in millions of CN￥): Clinical Trial Solutions: 3,500; Laboratory Services: 1,200; Data Management and Statistical Analysis: 800.